Literature DB >> 18782311

Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.

Matthias Waldert1, Andrea Haitel, Michael Marberger, Daniela Katzenbeisser, Mehmet Ozsoy, Elisabeth Stadler, Mesut Remzi.   

Abstract

OBJECTIVE: To compare the pathological features of clear cell renal cell carcinoma (ccRCC) with papillary RCC (pRCC) and further differentiate type I and II pRCC as independent prognosticators for survival. PATIENTS AND METHODS: From September 1994 to February 2007 557 RCCs were treated and reviewed. All patients underwent radical nephrectomy or nephron-sparing surgery. We reviewed patient data and correlated RCC subtypes to tumour size, pathological stage, nuclear grade, and 5-year cancer-specific survival (CSS). pRCC was re-evaluated in to type I and II. The 2002 Tumour-Node-Metastasis and Fuhrman classifications were used.
RESULTS: In all, 391 (70%) patients had ccRCC, 96 (17%) had pRCC, 34 (6%) had chromophobe RCC, seven (1%) had ductus Bellini RCC and 29 (5%) had unclassified RCC. Upon re-evaluation 34 patients had type I pRCC and 62 had type II. The pRCCs were significantly smaller than the ccRCCs, at a mean (sd) of 4.5 (2.5) cm vs 5 (2.9) cm (P = 0.013), and multifocal (25% vs 12%, P = 0.001). Whereas patients with ccRCC had significantly more primary metastases (12% vs 3%, P = 0.014). The mean (sd) follow-up was 42.3 (41.4) months. The 5-year CSS for M0 patients was 84% for ccRCC and 90% for pRCC (P = 0.573). At multivariate analyses predictors for 5-year CSS were only tumour size (hazard ratio, HR 2.6, P < 0.001), pathological stage (HR 3.9, P < 0.001) and nuclear grade (HR 2.7, P < 0.001). The type I and II pRCCs had significantly different lymphovascular invasion (LVI) and 5-year CSS rates (94% vs 74%, P = 0.03).
CONCLUSIONS: The ccRCCs were significantly larger at diagnosis than the pRCCs. The histological subtype (pRCC vs ccRCC) had no impact on the 5-year CSS in multivariate analyses. The type I and II pRCCs had similar histopathological features except for a significant difference in LVI. However, the 5-year CSS was significantly different in type I and II pRCC.

Entities:  

Mesh:

Year:  2008        PMID: 18782311     DOI: 10.1111/j.1464-410X.2008.07999.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

Review 1.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  The role of minimally invasive surgery in multifocal renal cell carcinoma.

Authors:  Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  Curr Urol Rep       Date:  2012-06       Impact factor: 3.092

3.  Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).

Authors:  Ayal A Aizer; Yuksel Urun; Rana R McKay; Adam S Kibel; Paul L Nguyen; Toni K Choueiri
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

4.  CT texture analysis for the differentiation of papillary renal cell carcinoma subtypes.

Authors:  Chongfeng Duan; Nan Li; Lei Niu; Gang Wang; Jiping Zhao; Fang Liu; Xuejun Liu; Yande Ren; Xiaoming Zhou
Journal:  Abdom Radiol (NY)       Date:  2020-11

5.  Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.

Authors:  Giuseppe Rosiello; Carlotta Palumbo; Sophie Knipper; Angela Pecoraro; Stefano Luzzago; Pierre-Antoine St-Hilaire; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz
Journal:  World J Urol       Date:  2020-04-06       Impact factor: 4.226

6.  Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Authors:  Alcides Chaux; Luciana Schultz; Roula Albadine; Jessica Hicks; Jenny J Kim; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

7.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 8.  Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.

Authors:  Theodore F Logan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

Review 9.  Molecular targets on the horizon for kidney and urothelial cancer.

Authors:  Joaquim Bellmunt; Bin T Teh; Giampaolo Tortora; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

10.  Renal cell carcinoma with rhabdoid-like features lack intracytoplasmic inclusion bodies and show aggressive behavior.

Authors:  Masaaki Sugimoto; Kenichi Kohashi; Kentaro Kuroiwa; Tatsuro Abe; Yuichi Yamada; Masaki Shiota; Kenjiro Imada; Seiji Naito; Yoshinao Oda
Journal:  Virchows Arch       Date:  2015-12-09       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.